Prevalence, proportions of elevated liver enzyme levels, and long-term cardiometabolic mortality of patients with metabolic dysfunction-associated steatotic liver disease.
Chen YT, Chen TI, Yin SC, Huang CW, Huang JF, Lu SN, Yeh ML, Huang CF, Dai CY, Chen YW, Chuang WL, Yu ML, Lee MH.
Chen YT, et al. Among authors: huang jf.
J Gastroenterol Hepatol. 2024 May 9. doi: 10.1111/jgh.16592. Online ahead of print.
J Gastroenterol Hepatol. 2024.
PMID: 38725327
BACKGROUND AND AIM: This study estimated the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) according to cardiometabolic risk factors. The long-term impacts of MASLD on all-cause and cardiometabolic-specific mortality were evaluated. ...
BACKGROUND AND AIM: This study estimated the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) according to car …